Edition:
United States

Eli Lilly and Co (LLY.N)

LLY.N on New York Stock Exchange

67.71USD
2 Dec 2016
Change (% chg)

$1.74 (+2.64%)
Prev Close
$65.97
Open
$66.34
Day's High
$68.38
Day's Low
$65.96
Volume
2,391,213
Avg. Vol
1,285,711
52-wk High
$88.16
52-wk Low
$64.25

LLY.N

Chart for LLY.N

About

Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company's human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.... (more)

Overall

Beta: 0.30
Market Cap(Mil.): $84,606.59
Shares Outstanding(Mil.): 1,103.95
Dividend: 0.51
Yield (%): 2.66

Financials

  LLY.N Industry Sector
P/E (TTM): 33.28 29.13 29.87
EPS (TTM): 2.30 -- --
ROI: 8.54 15.56 14.95
ROE: 15.87 16.69 16.29

US STOCKS-S&P 500 dips with healthcare shares, Dow edges up ahead of holiday

* Dow up 0.1 pct, S&P down 0.1 pct, Nasdaq down 0.3 pct (Updates to late afternoon, adds dateline)

Nov 23 2016

BRIEF-Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

* Eli Lilly and CO incoming CEO David Ricks on CNBC - Amyloid Hypothesis should be continued to be studied in reference to its Alzheimer's drug

Nov 23 2016

BRIEF-Paulson & Co cuts share stake in Pfizer, raises share stake in Facebook

* Paulson & Co Inc raises share stake in Facebook Inc by 47.3 percent to 212,700 Class A shares

Nov 14 2016

BRIEF-Eli lilly and Incyte says Baricitinib treatment show improvements in rheumatoid arthritis symptoms in phase 3

* Eli lilly -new analyses of phase 3 trials show improvements in rheumatoid arthritis symptoms following treatment with Baricitinib Source text for Eikon: Further company coverage:

Nov 14 2016

BRIEF-Eli Lilly and Co says new data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes

* New data from pivotal RA-BEACON study show significant improvement in patient-reported outcomes in rheumatoid arthritis patients treated with baricitinib compared to placebo

Nov 02 2016

BRIEF-Eli Lilly and Co sets quarterly dividend of $0.51/share

* Sets quarterly dividend of $0.51 per share Source text for Eikon: Further company coverage:

Oct 17 2016

Regeneron, Teva take aim at Lilly/Pfizer pain drug

Sept 20 Regeneron Pharmaceuticals Inc and Israeli drugmaker Teva Pharmaceutical Industries on Tuesday said they would co-develop Regeneron's experimental new type of pain drug and together market the medicine if it succeeds in trials and is approved.

Sep 20 2016

BRIEF-EMA recommends approval of three new cancer treatments

* Recommends approval of Eli Lilly and Boehringer Ingelheim's Glyxambi for treatment of type 2 diabetes

Sep 16 2016

BRIEF-Levi Garraway to become senior vice president of global oncology at Lilly

* Levi garraway, m.d., ph.d., to become senior vice president of global oncology at lilly, succeeding richard gaynor, m.d., who is retiring after a distinguished career

Sep 14 2016

BRIEF-Lilly-Health Canada approves new indication for Jardiance tablets

* Health Canada approves new indication for Jardiance (empagliflozin) tablets for adults with type 2 diabetes and established cardiovascular disease Source text for Eikon: Further company coverage:

Aug 11 2016

Competitors

Earnings vs. Estimates